Stockreport

Galecto Highlights Key Strategic Priorities and Anticipated 2026 Milestones [Yahoo! Finance]

Galecto, Inc.  (GLTO) 
PDF equivalent, in mid-2026 with anticipated first-in-human dosing via subcutaneous administration Recent addition of deep hematology/oncology drug development experience [Read more]